311 related articles for article (PubMed ID: 28081475)
21. [Efficacy of carbamazepine, valproate and topiramate in the treatment of medial temporal epilepsy in children].
Boldyreva SR; Ermakov AIu
Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(4):41-7. PubMed ID: 20517209
[TBL] [Abstract][Full Text] [Related]
22. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group.
Chiron C; Marchand MC; Tran A; Rey E; d'Athis P; Vincent J; Dulac O; Pons G
Lancet; 2000 Nov; 356(9242):1638-42. PubMed ID: 11089822
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic Variability During Long-Term Therapeutic Drug Monitoring of Valproate, Clobazam, and Levetiracetam in Patients With Dravet Syndrome.
Johannessen Landmark C; Heger K; Lund C; Burns ML; Bjørnvold M; Sætre E; Johannessen SI
Ther Drug Monit; 2020 Oct; 42(5):744-753. PubMed ID: 32558674
[TBL] [Abstract][Full Text] [Related]
24. Differential cognitive and behavioral effects of topiramate and valproate.
Meador KJ; Loring DW; Hulihan JF; Kamin M; Karim R;
Neurology; 2003 May; 60(9):1483-8. PubMed ID: 12743236
[TBL] [Abstract][Full Text] [Related]
25. Impact of age, gender and CYP2C9/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid-a large-scale study based on naturalistic therapeutic drug monitoring data.
Smith RL; Haslemo T; Refsum H; Molden E
Eur J Clin Pharmacol; 2016 Sep; 72(9):1099-104. PubMed ID: 27353638
[TBL] [Abstract][Full Text] [Related]
26. Characterization of the anticonvulsant, behavioral and pharmacokinetic interaction profiles of stiripentol in combination with clonazepam, ethosuximide, phenobarbital, and valproate using isobolographic analysis.
Luszczki JJ; Ratnaraj N; Patsalos PN; Czuczwar SJ
Epilepsia; 2006 Nov; 47(11):1841-54. PubMed ID: 17116023
[TBL] [Abstract][Full Text] [Related]
27. Impact of CYP2C19 and CYP2C9 gene polymorphisms on sodium valproate plasma concentration in patients with epilepsy.
Song C; Li X; Mao P; Song W; Liu L; Zhang Y
Eur J Hosp Pharm; 2022 Jul; 29(4):198-201. PubMed ID: 32868386
[TBL] [Abstract][Full Text] [Related]
28. Effects of CYP2C19 and P450 oxidoreductase polymorphisms on the population pharmacokinetics of clobazam and N-desmethylclobazam in japanese patients with epilepsy.
Saruwatari J; Ogusu N; Shimomasuda M; Nakashima H; Seo T; Tanikawa K; Tsuda Y; Nishimura M; Nagata R; Yasui-Furukori N; Kaneko S; Ishitsu T; Nakagawa K
Ther Drug Monit; 2014 Jun; 36(3):302-9. PubMed ID: 24345815
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and tolerability of the ketogenic diet in Dravet syndrome - Comparison with various standard antiepileptic drug regimen.
Dressler A; Trimmel-Schwahofer P; Reithofer E; Mühlebner A; Gröppel G; Reiter-Fink E; Benninger F; Grassl R; Feucht M
Epilepsy Res; 2015 Jan; 109():81-9. PubMed ID: 25524846
[TBL] [Abstract][Full Text] [Related]
30. Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy.
Rosenfeld WE; Liao S; Kramer LD; Anderson G; Palmer M; Levy RH; Nayak RK
Epilepsia; 1997 Mar; 38(3):324-33. PubMed ID: 9070595
[TBL] [Abstract][Full Text] [Related]
31. Stiripentol (Diacomit) for Dravet syndrome.
Med Lett Drugs Ther; 2021 Mar; 63(1620):e48-e50. PubMed ID: 33976090
[No Abstract] [Full Text] [Related]
32. Topiramate in the treatment of highly refractory patients with Dravet syndrome.
Kröll-Seger J; Portilla P; Dulac O; Chiron C
Neuropediatrics; 2006 Dec; 37(6):325-9. PubMed ID: 17357033
[TBL] [Abstract][Full Text] [Related]
33. [Comparative efficacy of carbamazepine, valproic acid and topiramate in symptomatic and cryptogenic occipital lobe epilepsy in children].
Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(5 Suppl 1):39-44. PubMed ID: 20559266
[TBL] [Abstract][Full Text] [Related]
34. Current therapeutic procedures in Dravet syndrome.
Chiron C
Dev Med Child Neurol; 2011 Apr; 53 Suppl 2():16-8. PubMed ID: 21504427
[TBL] [Abstract][Full Text] [Related]
35. [Comparative efficacy of carbamazepine, valproic acid and topiramate in symptomatic and cryptogenic frontal lobe epilepsy in children].
Boldyreva SR; Ermakov AIu
Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(6):58-65. PubMed ID: 20559276
[TBL] [Abstract][Full Text] [Related]
36. Starting stiripentol in adults with Dravet syndrome? Watch for ammonia and carnitine.
Zulfiqar Ali Q; Marques P; Selvarajah A; Tabarestani S; Sadoway T; Andrade DM
Epilepsia; 2020 Nov; 61(11):2435-2441. PubMed ID: 33084037
[TBL] [Abstract][Full Text] [Related]
37. Early post-traumatic seizures are associated with valproic acid plasma concentrations and UGT1A6/CYP2C9 genetic polymorphisms in patients with severe traumatic brain injury.
Sun Y; Yu J; Yuan Q; Wu X; Wu X; Hu J
Scand J Trauma Resusc Emerg Med; 2017 Aug; 25(1):85. PubMed ID: 28841884
[TBL] [Abstract][Full Text] [Related]
38. The European patient with Dravet syndrome: results from a parent-reported survey on antiepileptic drug use in the European population with Dravet syndrome.
Aras LM; Isla J; Mingorance-Le Meur A
Epilepsy Behav; 2015 Mar; 44():104-9. PubMed ID: 25666511
[TBL] [Abstract][Full Text] [Related]
39. Effect of CYP2C19 polymorphisms on the clinical outcome of low-dose clobazam therapy in Japanese patients with epilepsy.
Hashi S; Yano I; Shibata M; Masuda S; Kinoshita M; Matsumoto R; Ikeda A; Takahashi R; Matsubara K
Eur J Clin Pharmacol; 2015 Jan; 71(1):51-8. PubMed ID: 25323806
[TBL] [Abstract][Full Text] [Related]
40. The effects of valproate and topiramate use on serum insulin, leptin, neuropeptide Y and ghrelin levels in epileptic children.
Çiçek NP; Kamaşak T; Serin M; Okten A; Alver A; Cansu A
Seizure; 2018 May; 58():90-95. PubMed ID: 29679911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
